bioMérieux S.A
Research bioMérieux S.A (EYWN) on Bullrun: market cap EUR 8.62B, P/E 18.8, dividend yield 1.3%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerEYWN
- ExchangeF
- CountryFrance
- SectorHealthcare
- IndustryDiagnostics & Research
- CurrencyEUR
- Market capEUR 8.62B
- P/E18.8
- Dividend yield1.3%
- Financial periodFY2025
- RevenueEUR 4.07B
- Revenue growth2.3%
- Net incomeEUR 397.50M
- Free cash flowEUR 453.10M
- Gross margin56.7%
Valuation Snapshot
latest market cap is EUR 8.62B; P/E is 18.8; dividend yield is 1.3%.
Peer valuation comparison
Latest P/E is 18.77x versus a Healthcare sector median of 24.46x (23.3% below).
Latest dividend yield is 1.3% versus a Healthcare sector median of 2.11% (38.4% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 4.07B | EUR 397.50M | EUR 453.10M | 56.7% | 3.34 | EUR 569.80M | EUR 461.40M | EUR 4.10B |
| FY2024 | EUR 3.98B | EUR 432.20M | EUR 321.50M | 55.7% | 3.64 | EUR 449.80M | EUR 490.20M | EUR 4.20B |
| FY2023 | EUR 3.67B | EUR 357.60M | EUR 107.10M | 56.0% | 3.01 | EUR 352.40M | EUR 518.90M | EUR 3.75B |
| FY2022 | EUR 3.59B | EUR 452.40M | EUR 188.40M | 56.0% | 3.82 | EUR 552.60M | EUR 505.40M | EUR 3.60B |
| FY2021 | EUR 3.38B | EUR 598.20M | n/a | 59.3% | 5.06 | EUR 803.50M | n/a | EUR 3.11B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | EUR 8.62B | 18.8 | 1.3% | 0.98 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0.98 EUR, yield 1.3%.
| Year | Dividends/share |
|---|---|
| FY2025 | 0.9 EUR |
| FY2024 | 0.85 EUR |
| FY2023 | 0.85 EUR |
| FY2022 | 0.85 EUR |
| FY2021 | 0.62 EUR |
About bioMérieux S.A
bioMérieux S.A. develops, manufactures, and markets in vitro diagnostic solutions for infectious diseases in France, Europe, Africa, the Middle East, North and South America, the Asia Pacific, and internationally. It operates through Clinical Applications and Industrial Applications segments. The company offers CHROMID RANGE, a chromogen culture media; air, surface, and water monitoring systems; BACT/ALERT VIRTUO, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction system (PCR);
Related stock research
Other Healthcare stocks
Frequently asked questions
What is bioMérieux S.A's market cap?
bioMérieux S.A's market capitalization is EUR 8.62B.
What is bioMérieux S.A's P/E ratio?
bioMérieux S.A's price-to-earnings (P/E) ratio is 18.8.
Does bioMérieux S.A pay a dividend?
bioMérieux S.A has a dividend yield of 1.3%.
What does bioMérieux S.A do?
bioMérieux S.A. develops, manufactures, and markets in vitro diagnostic solutions for infectious diseases in France, Europe, Africa, the Middle East, North and South America, the Asia Pacific, and internationally. It operates through Clinical Applications and Industrial Applications segments.